Literature DB >> 9038425

Clinical and magnetic resonance imaging changes correlate in a clinical trial monitoring cyclosporine therapy for multiple sclerosis. The MS Study Group.

G J Zhao1, D K Li, J S Wolinsky, R A Koopmans, W Mietlowski, W K Redekop, A Riddehough, K Cover, D W Paty.   

Abstract

Magnetic resonance imaging (MRI) was used to monitor cyclosporine therapy for chronic progressive multiple sclerosis in a multicenter clinical trial and an analysis was performed to determine whether there was a correlation between clinical changes and MRI changes. MRI was performed on 163 patients at the onset and completion of the 2-year study. Burden of disease (BOD, lesion load) was quantitated by a single observer using a computer program. Active lesions were also identified. The Expanded Disability Status Scale (EDSS) score was determined every 3 months MRI data did not show any effect of cyclosporine treatment on BOD progression (mean 24.5% increase/yr) or lesion activity. However, there was a statistically significant positive correlation between the baseline total BOD value and the baseline EDSS score (r = 0.221, p = 0.005) and a positive correlation between the percent changes in BOD from baseline to exit and EDSS score (r = 0.186, p = 0.018). The study supports the concepts that MRI is a useful technique in monitoring therapeutic trials and that MRI is a direct measure of pathology.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9038425     DOI: 10.1111/jon1997711

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  9 in total

1.  MR imaging of brain volumes: evaluation of a fully automatic software.

Authors:  K Ambarki; A Wåhlin; R Birgander; A Eklund; J Malm
Journal:  AJNR Am J Neuroradiol       Date:  2010-11-04       Impact factor: 3.825

Review 2.  Imaging of multiple sclerosis: role in neurotherapeutics.

Authors:  Rohit Bakshi; Alireza Minagar; Zeenat Jaisani; Jerry S Wolinsky
Journal:  NeuroRx       Date:  2005-04

3.  Evaluation of automatic measurement of the intracranial volume based on quantitative MR imaging.

Authors:  K Ambarki; T Lindqvist; A Wåhlin; E Petterson; M J B Warntjes; R Birgander; J Malm; A Eklund
Journal:  AJNR Am J Neuroradiol       Date:  2012-05-03       Impact factor: 3.825

4.  Precision and reliability for measurement of change in MRI lesion volume in multiple sclerosis: a comparison of two computer assisted techniques.

Authors:  P D Molyneux; P S Tofts; A Fletcher; B Gunn; P Robinson; H Gallagher; I F Moseley; G J Barker; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-07       Impact factor: 10.154

5.  The role of qualitative and quantitative MRI assessment of multiple sclerosis lesions according to their in evaluating the efficacy of intravenous immunoglobulin G.

Authors:  B Koçer; S Yildirim-Gürel; E T Tali; C Irkeç; S Işik
Journal:  Neuroradiology       Date:  2004-03-04       Impact factor: 2.804

6.  Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis.

Authors:  Michael Forte; Bruce G Gold; Gail Marracci; Priya Chaudhary; Emy Basso; Dustin Johnsen; Xiaolin Yu; Jonathan Fowlkes; Micha Rahder; Katie Stem; Paolo Bernardi; Dennis Bourdette
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-26       Impact factor: 11.205

Review 7.  Oral disease-modifying treatments for multiple sclerosis: the story so far.

Authors:  Bernd C Kieseier; Heinz Wiendl
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 8.  Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy.

Authors:  Alexander J Gill; Dennis L Kolson
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

9.  A narrative review of psoriasis and multiple sclerosis: links and risks.

Authors:  Annika S Silfvast-Kaiser; Katie B Homan; Bobbak Mansouri
Journal:  Psoriasis (Auckl)       Date:  2019-08-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.